
Quiz|Articles|March 6, 2026
OncLive Weekly News Quiz (3/6/2026): Brush Up on Regulatory Splashes in Myeloma, RCC, and PV
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA recently approved teclistamab-cqyv (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of patients with relapsed/refractory multiple myeloma after at least 1 prior line of therapy, after the regulatory agency reviewed the application under the FDA Commissioner’s National Priority Review Voucher pilot program. The decision followed which February oncology approval that was also reviewed under the same program?
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5






































































